181 related articles for article (PubMed ID: 22873289)
1. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
Rathos MJ; Joshi K; Khanwalkar H; Manohar SM; Joshi KS
J Transl Med; 2012 Aug; 10():161. PubMed ID: 22873289
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
3. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
4. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
Mishra PB; Lobo AS; Joshi KS; Rathos MJ; Kumar GA; Padigaru M
J Transl Med; 2013 Feb; 11():42. PubMed ID: 23414419
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
7. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
8. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Rathos MJ; Khanwalkar H; Joshi K; Manohar SM; Joshi KS
BMC Cancer; 2013 Jan; 13():29. PubMed ID: 23343191
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
11. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
[TBL] [Abstract][Full Text] [Related]
12. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Zheng C; Jiao X; Jiang Y; Sun S
J Int Med Res; 2013 Apr; 41(2):300-6. PubMed ID: 23569008
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
14. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
15. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
16. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Ou YQ; Zhu Wb; Li Y; Qiu PX; Huang YJ; Xie J; He SM; Zheng XK; Leng TD; Xu D; Yan GM
Acta Pharmacol Sin; 2010 Jan; 31(1):73-80. PubMed ID: 19966835
[TBL] [Abstract][Full Text] [Related]
17. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
18. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
19. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]